Ionis Pharmaceuticals (IONS) partner GSK (GSK) announced the FDA has accepted for priority review the new drug application, or NDA, for bepirovirsen, an investigational antisense oligonucleotide, or ASO, for the treatment of adults with chronic hepatitis B. The FDA has granted bepirovirsen breakthrough therapy designation and set a Prescription Drug User Fee Act target action date of October 26.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals Inc. (IONS) Q1 Earnings Cheat Sheet
- Ionis Pharmaceuticals price target lowered to $108 from $110 at TD Cowen
- Ionis Pharmaceuticals: Advancing Neurology Franchise Underscored by Zilganersen’s Strong Phase III Data in Alexander Disease
- Ionis Expands Its Rare Epilepsy Pipeline With New ASCEND Trial in Dravet Syndrome
- Ionis Pharmaceuticals price target raised to $130 from $95 at Morgan Stanley